Synairgen PLC

Synairgen PLC is a United Kingdom-based holding company engaged in the drug discovery and development business . The Company's primary focus is developing SNG001 (inhaled interferon beta) as a host-targeted, antiviral treatment delivered directly into the lungs for the treatment of viral lung infections, including COVID-19.